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To explore the feasibility of detecting salivary levels of IFN-γ,T N F - α, and sTNFR-2 from erosive oral lichen planus (ELP) patients
for clinical application, 20 ELP patients were enrolled in the study as were 20 age-sex-matched controls. From all subjects, saliva
levelofthetestedbiomarkerswasdeterminedbyELISA.SalivaryproﬁleswereassessedinELPpatientsbyELISAafterbeingtreated
with prednisone. A signiﬁcantly higher level of IFN-γ (P ≤ .01), TNF-α (P ≤ .0001), and sTNFR-2 (P ≤ .01) was detected in ELP
patients before treatment than in controls. Following treatment, the salivary levels of IFN-γ (P ≤ .01), TNF-α (P ≤ .05), and
sTNFR-2 (P ≤ .01) decreased signiﬁcantly when compared to their pretreatment levels. This study demonstrated that salivary
IFN-γ,T N F - α, and sTNFR-2 can be detectable in ELP patients and decreased signiﬁcantly after treatment with prednisone, which
may reveal the possibility of using these disease-related biomarkers in diagnosis and monitoring.
1.Introduction
Oral lichen planus (OLP) is a chronic inﬂammatory con-
dition involving the oral mucosal tissues [1]. Although
the mechanisms of OLP pathogenesis have not been fully
disclosed, it has been suggested that autoreactive cytotoxic
CD8+ T-cells trigger keratinocytes apoptosis in OLP [2].
Evidence has shown that a complex cytokine network plays
an important role in the exacerbation and perpetuation
of OLP; hence, TNF-α and IFN-γ have been extensively
studied and were proven by many investigators to have a key
regulatory role in the immunopathogenesis of OLP [3, 4].
Being a Th1 cytokine, IFN-γ is involved in the activation
of CD8+ cytotoxic T-cells and maintains keratinocytes
major histocompatibility class II expression in OLP, thereby
contributing to disease chronicity [2, 5].
Cell-mediated immunity in OLP may be regulated by
various cytokines and their receptors [5]. TNF-α is a
highly pleiotropic, multifunctional cytokine that regulates
diverse cellular responses via binding to two distinct cell
surface receptors: TNF receptor-1 (TNFR-1/60kDa) and
TNF receptor-2 (TNFR-2/80kDa) [6]. Apoptosis is seen as
a general TNF-α-mediated cytotoxic phenomenon occurring
through the TNFR-1 signaling pathway [7]. Sugerman et al.
[2] suggested that one of the possible mechanisms used by
CD8+ cytotoxic T-cells to trigger keratinocyte apoptosis in
OLP included the T-cell-secreted TNF-α binding to TNFR-
1 on the keratinocyte surface. This binding may activate
the keratinocyte caspase cascade resulting in keratinocyte
apoptosis.
Previous studies showed that many cell types coexpress
TNFR-1 and TNFR-2 and require collaboration between
these two receptors to generate TNF-α-mediated apoptosis
[8, 9]. Furthermore, several investigations have reported that
TNFR-2 may play an important role in the induction of
TNFR-1-mediated apoptosis [10, 11]. Accordingly, it would
be of interest to study the soluble TNFR-2 (sTNFR-2) levels
in OLP patients, given that to the best of our knowledge,2 Mediators of Inﬂammation
Table 1: The characteristics of subjects.
Age (years) Gender
Mean ± SD range F/M
OLP (n = 20) 46.3 ± 4.99 40–55 18/2
Control (n = 20) 42 ± 7.2 39–55 17/3
sTNFR-2 proﬁles have only been assessed in the serum of
patients with cutaneous LP [12].
Saliva has more potential diagnostic value that is gen-
erally appreciated and has promise to be an aid in the
diagnosisofsystemicandoraldiseasesinthelastdecade[13].
Whole saliva oﬀersdistinctive advantagesoverother research
mediums such as serum, lesional tissues, and lesional
transudates in that individuals with modest training could
repeatedly collect it noninvasively [14]. Hence, it provides a
cost-eﬀective approach for disease monitoring and screening
of large populations [15]. Whole saliva has been successfully
applied for detection of proinﬂammatory cytokines and
adhesion molecules in several immunologically mediated
diseases [16, 17].
It is important to evaluate the practical application
of salivary biomarkers’ analyses in clinical management of
OLP [18]. Accordingly, several studies in the literature have
demonstrated the signiﬁcance of OLP-related cytokines in
monitoring treatment [4, 19]. However, minimal studies
have explored the potential of cytokines’ receptors in OLP
patients for clinical application. Consequently, the purpose
of the current study was to investigate the possibility
of detecting diﬀerent disease-related biomarkers’ including
TNF-α,I F N - γ, and sTNFR-2 in saliva of erosive OLP
(ELP) patients and to monitor the therapeutic response by
determining their levels before and after treatment with a
systemic corticosteroid, prednisone.
2.MaterialandMethods
2.1. Study Population. The entire study sample comprised 40
subjects: 20 patients suﬀering from ELP (18 female, 2 male;
range 40 to 55 years) and 20 healthy controls (17 female, 3
male;range41to56years).Thepatientswerediagnosedwith
ELP; while the controls were healthy normal individuals free
form any systemic disease or inﬂammatory oral lesions. The
distribution of subjects according to the age and gender is
presented in Table 1.
2.2. Inclusion and Exclusion Criteria. Subjects were selected
from the Outpatient Clinic, Department of Oral Medicine
and Periodontology, Faculty of Oral and Dental Medicine,
Cairo University. A detailed medical history of each subject
was obtained according to the detailed questionnaire of
the modiﬁed Cornell Medical Index [20]. All subjects were
free from any systemic disease and did not receive any
medication either topical or systemic that could cause
lichenoid reaction during the 3 months before the study.
Moreover, patients with suspected restoration-related reac-
tion or gingival inﬂammation were excluded from this study.
Written consent was obtained from each subject who signed
an informed consent form approved by the University Insti-
tutional Review Board. This was followed by an explanation
of the study as well as information about the treatment and
follow-up appointments needed.
All patients had oral symptoms, and every case was
clinically diagnosed as ELP. Duration of the disease ranged
from 2 to 3 months with periods of remission and exac-
erbation. The erosive lesions were bilateral and extended
to involve the buccal mucosa, labial mucosa, and tongue
which varied from one patient to the other. Diagnosis was
conﬁrmed by histopathologic examination according to the
World Health Organization’s (WHO’s) clinicopathological
diagnostic criteria for LP [21].
According to Carbone et al. [22], ELP patients were
treatedwithsystemicprednisone,at40–60mg/dayinasingle
morning dose for variable lengths of time, anyhow not up
t o6 0d a y s .W h e na na l m o s t5 0 %r e d u c t i o ni nl e s i o ns i z e
was achieved, the prednisone dose was tapered by reducing
10mg each week and ﬁnally to 5mg/day for the last week.
Patients were checked every week, and the dose and length
of the treatment were adjusted in each case following the
clinical needs. Patients were instructed not to use any other
medication for the treatment of ELP during this study
period.
2.3. Collection of Samples
2.3.1. Salivary Sample Collection. Collection of whole un-
stimulatedsaliva(WUS)wasdoneusingstandardtechniques
according to Navazesh [23]. At the time of saliva collection,
lesions were actively symptomatic. Salivary samples were
obtained in the morning and subjects were asked not
to eat, brush their teeth, or use mouth rinse at least
2 hours prior to salivary sample collection on that day.
Samples were obtained by requesting subjects to swallow
ﬁrst, tilt their head forward, and expectorate 10mL of
unstimulated whole saliva into a sterile centrifuge tube.
After collection, the saliva was immediately centrifuged
for 2min at 10,000×g and the clariﬁed supernatant was
ﬁltered through a 0.45μm low protein binding membrane,
separated into 0.5mL aliquots and frozen at −80◦C until
assayed.
2.3.2. Detection of Salivary Levels of IFN-γ,T N F - α,a n d
sTNFR-2. Theevaluationinthisstudyincludedassessingthe
levels of IFN-γ,T N F - α, and sTNFR-2 in saliva of patients
with ELP before and after treatment with prednisone. After
collecting all the salivary samples, the studied biomarkers
were assessed by ELISA.
2.3.3. Determination of IFN-γ in Salivary Samples. Saliva
samples were determined by using a commercially available
enzyme-linked immunosorbent assay (ELISA) kit (R&D
Systems Inc., Minneapolis, MN, USA). This assay employs
the quantitative sandwich enzyme immunoassay technique.
A polyclonal antibody speciﬁc for IFN-γ has been precoatedMediators of Inﬂammation 3
ontoamicroplate.Standardsandsamples(100μLeac h)w er e
pipetted into the wells in duplicate, and any IFN-γ present
was bound by the immobilized antibody. After washing
away any unbound substances, an enzyme-linked polyclonal
antibody speciﬁc for IFN-γ (200μL) was added to the wells
for 2 hours. Following a wash to remove any unbound
antibody-enzyme reagent, a substrate solution (200μL) was
added to the wells for 30min and color developed in
proportion to the amount of IFN-γ bound in the initial step.
The yellow color development was stopped, and the intensity
of the blue color was measured by measuring absorbance
at 450nm, with the correction wavelength set at 540nm or
570nm.Theminimumdetectabledose (MDD)ofIFN-γ was
typically less than 8.0pg/mL. The concentrations of samples
were calculated from the standard curve, and the results
were presented in picogram per milliliter (pg/mL). The
concentrationsofthecurvewererangedfrom0–1000pg/mL.
2.3.4. Determination of TNF-α and sTNFR-2 in Saliva.
Levels of TNF-α and sTNFR-2 in saliva samples were deter-
mined by using a commercially available enzyme-linked
immunosorbent assay (ELISA) kit (R&D Systems Inc.).
These are standard “sandwich” ELISAs and were per-
formed using human recombinant standards according
to the manufacturer’s instructions. These assays employ
the quantitative sandwich enzyme immunoassay technique.
A monoclonal antibody speciﬁc for TNF-α and sTNFR-
2 has been precoated onto a microplate. Standards and
samples (100μL each) in duplicate, were pipetted into the
speciﬁc wells, and any TNF-α and/or sTNFR-2 present
was bound by the immobilized antibody. After washing
away any unbound substances, an enzyme-linked poly-
clonal antibody (200μL) speciﬁc for TNF-α and sTNFR-
2 was added to the speciﬁc wells. Following a wash to
remove any unbound antibody-enzyme reagent, a substrate
solution (200μL) was added to the speciﬁc wells and
yellow color developed in proportion to the amount of
TNF-α and/or sTNFR-2 bound in the initial step. The
color development was stopped, and the intensity of the
blue color was measured. These assays have a lower limit
of detection for TNF-α (1.6pg/mL) and for sTNFR-2
(0.6pg/mL). Concentrations of the cytokine and its soluble
receptor in the sample were determined by generation
of a standard curve for comparison, and results were
presented in pg/mL. The TNF-α standard curve ranged from
(0–1000pg/mL) while that of sTNFR-2 ranged from (0–
500pg/mL)
2.4. Statistical Analysis. Results were expressed as mean ±
standard deviation (SD) and median. First “one way
ANOVA” was performed to demonstrate the diﬀerence of
each biomarker level between ELP and control group in
saliva. Then, “repeated measures ANOVA” was used for
comparison of the change of each biomarker level in saliva
before and after treatment in ELP group. All data were
processed with a computerized statistical package (SPSS 15.0
for Windows, SPSS Inc., Chicago, IL.) (MedCalc Software
11.4.4 for Windows, Mariakerke, Belgium).
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Figure 1: Salivary levels of IFN-γ measured in pg/mL from control
subjects compared with levels in ELP patients before and after
treatment with prednisone.
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Figure 2: Salivary levels of TNF-α measured in pg/mL from control
subjects compared with levels in ELP patients before and after
treatment with prednisone.
3. Results
IFN-γ,T N F - α, and sTNFR-2 were detected in all saliva
samples obtained from healthy subjects. The levels of the
IFN-γ,T N F - α,a n ds T N F R - 2( P = .009) in saliva increased
remarkably in the ELP group than those in the controls. The
highest signiﬁcance (P = .0001) was observed when both
TNF-α and IFN-γ concentrations in saliva were compared
to their corresponding control groups (Table 2). Following
treatment with systemic prednisone, the salivary levels of
IFN-γ (P = .001), TNF-α (P = .0263), and sTNFR-2
(P = .01) decreased signiﬁcantly when compared to their
pretreatment levels (Table 2 and Figures 1, 2,a n d3).4 Mediators of Inﬂammation
Table 2: The change of IFN-γ,T N F - α, and TNFR-2 salivary levels in ELP patients treated with prednisone and control subjects.
IFN-γ TNF-α TNFR-2
ELP before treatment Mean ± SD 23.953 ± 5.33 44.485 ± 16.81 350.4 ± 330.89
Median 18.30 55.60 1029
ELP after treatment Mean ± SD 17.237 ± 5.68 21.33 ± 17.21 14.0 ± 11.39
Median 15.39 54.30 31
Control Mean ± SD 6.41 ± 2.53 1.405 ± 0.25 45 ± 13.82
Median 6.09 0.90 43
Before versus after P value P ≤ .001 P ≤ .05 P ≤ .01
Before versus control P value P ≤ .0001 P ≤ .0001 P ≤ .01
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Figure 3: Salivary levels of sTNFR-2 measured in pg/mL from
control subjects compared with levels in ELP patients before and
after treatment with prednisone.
4. Discussion
Salivary assays have shown to have a signiﬁcant correlation
with lesional tissue partners [24]a n ds e r u mp a r t n e r si nO L P
patients [14]. Considering that whole saliva is a complex
mixture derived from the salivary glands, along with contri-
butions from the gingival crevicular ﬂuid (GCF) and other
sources [13], and that biochemical markers can be secreted
through GCF, therefore, subjects in this study were selected
without any gingival inﬂammation that could confound
the present results using saliva as the research media. As
the enhanced expression of disease-related cytokines and
their soluble receptors has been demonstrated by previous
reports to contribute to the pathogenesis of OLP [4, 5,
16], it is reasonable for clinicians to focus on the clinical
application of detecting these biomarkers. Accordingly, the
current study focused on the salivary proﬁles of INF-γ,T N F -
α, and sTNFR-2 in ELP patients in response to treatment
with prednisone in an attempt to reveal the possibility of
their use in disease diagnosis and monitoring. Since systemic
corticosteroids are indicated for patients with severe erosive
or atrophic OLP [22] and wide spread lesions [25] owing
to their anti-inﬂammatory and immunosuppressive eﬀects
[26, 27], prednisone was chosen in this study being the most
widelyusedsystemiccorticosteroidintreatmentofOLPwith
high rates of eﬃcacy (80–100%) [22].
The present study demonstrated a statistically signiﬁcant
elevation in salivary levels of TNF-α and INF-γ in OLP
samples compared to normal control. These data were con-
sistent with their enhanced expression previously reported
from diﬀerent media in OLP patients which supports their
important role in the pathogenesis of OLP [3, 5, 28,
29]. Our ﬁndings were also supported by other studies
investigatingthesalivarylevelsofTNF-αinOLPpatients[14,
16, 18]. Moreover, Pezelj-Ribaric et al. [30] demonstrated
signiﬁcantly higher amounts of salivary TNF-α in OLP
patients compared to healthy controls which even showed
correlation with disease severity being signiﬁcantly higher
in the erosive/atrophic type than in reticular type of OLP.
The NF-κB-dependent cytokines TNF-α, IL-1, IL-6, and IL-
8 were also detected at signiﬁcant elevated levels in three
types of oral ﬂuids, including saliva, from OLP patients [16].
Zhang et al. [14] even suggested that salivary assay may be a
moresensitivemethodtoreﬂecttheenhanceddisease-related
cytokine production when compared to serum.
To date, the results on IFN-γ in OLP have been incon-
sistent. The data presented in this study was supported by
a recent investigation showing that erythematous/ulcerated
OLP patients had a signiﬁcant higher level of IFN-γ in
lesions and saliva than control [24]. On the other hand,
Liu et al. [15] recently demonstrated low expression of
IFN-γ in saliva of patients with OLP claiming that it may
result from the counter-regulation of pathologically elevated
Th2-derived cytokines such as IL-4, involved in cellular
immunosuppression. In contrast, Khan et al. [5] could not
detect in vitro IL-4 secretion in any OLP lesional T-cell lines;
therefore, this suggestion still needs further research.
The increase of salivary cytokines in ELP patients
observed in this study might be due to local production
from cells of the inﬂammatory inﬁltration and/or by the
keratinocytes themselves [14]. It has been also suggested
that T-cell activation and cytokine production act locally
and are not reﬂected in peripheral blood [31]. Moreover,
the epithelia from OLP lesions have been previously shown
to produce TNF-α 10- to 20-fold greater than those in
keratinocytes from normal gingiva [32].Mediators of Inﬂammation 5
The current study illustrated a signiﬁcant decrease in
the salivary levels of TNF-α and IFN-γ after treatment with
prednisone which advocates the fact that they play an impor-
tant role in the inﬂammatory process and immunopatho-
genesis of OLP. Accordingly, it has been reported that the
number of TNF-α-positive mononuclear cells in erosive or
atrophic OLP patients signiﬁcantly decreased after treatment
with 0.1% ﬂuocinolone acetonide [4]. Recently, Youngnak-
Piboonratanakit et al. [19] also demonstrated that in situ
expression of IFN-γ was signiﬁcantly elevated in OLP
patients and decreased after treatment with 0.1% ﬂuoci-
nolone acetonide. Our results are also consistent with Rho-
dus et al. [18] who found statistically signiﬁcant reduction in
the salivary levels of NF-κB-dependent cytokines in patients
with ELP following treatment with dexamethasone mouth
wash. The authors indicated that detection of disease-related
cytokines in saliva indeed has some clinical potential in
monitoring therapeutic response and disease activity status
of OLP, which is strongly supported by the data presented in
this study.
Considering that TNF-α has a role in carcinogenesis and
that ELP has a greater rate of malignant evolution, this
stressesonthediagnosticandprognosticpotentialofsalivary
TNF-α and its receptors in OLP patients [30, 33]. Our
analysis, to the best of our knowledge, demonstrates for the
ﬁrst time that salivary levels of sTNFR-2 were signiﬁcantly
elevated in patients with ELP than those in healthy controls
and signiﬁcantly decreased after treatment with prednisone.
TNF-α may trigger apoptosis in OLP through inducing
diﬀerentiation and activation of CD8+ cytotoxic T-cells
[2]. Smyth and Johnstone [34]o ﬀered an alternative view
that TNF-α actively drives lymphoproliferation by signaling
through TNFR-2. This conclusion is supported by earlier
studies suggesting that TNFR-2 transmits signals important
for the proliferation of cytotoxic T-cells and excluded an
absolute requirement of a coexpression of TNFR-1 for
TNFR-2 signaling [35, 36]. While it is clear that TNF-
α-induced apoptosis requires TNFR-1 signaling [6], yet,
numerousstudieshavedescribedsynergisticactionofTNFR-
2 and TNFR-1 in the potentiation of cell death [37–40]. It
has been reported that overexpression of TNFR-2 can endow
cells with the ability to undergo TNF-α-induced apoptosis.
Several mechanisms have been proposed to explain this
observation, including TNFR-2 serving as high aﬃnity
trap for TNF-α that delivers TNF-α to TNFR-1 “ligand-
passing” [41], TNFR-2 assisting TNFR-1-mediated apoptosis
indirectly by the induction of endogenous TNF-α [11, 42],
and TNFR-2 enhancing and amplifying the apoptotic cell
death signal transduction from TNFR-1 by promoting a
caspase activating signal [43].
In light of the above-mentioned data, this study suggests
that TNF-α might trigger keratinocyte apoptosis in OLP via
both TNFR-1 and TNFR-2. The present study, in which the
authors duly recognize that the sample size was relatively
small, presents some preliminary results related to the
signiﬁcant expression of salivary sTNFR-2 in ELP patients
which may give some new insights to the pathogenesis of
OLP. Although further conclusions from these data must be
interpreted cautiously, additional studies are recommended
for evaluating the TNFR-1/TNFR-2 ratio and better under-
standing of the role of sTNFR-2 in the pathogenesis of OLP.
5. Conclusion
The current study demonstrated that the absolute concen-
trations of salivary IFN-γ,T N F - α,a n ds T N F R - 2c a nb e
detectable in ELP patients and decreased signiﬁcantly after
treatment with prednisone. The results of this study from
saliva of ELP patients provide a potential for specimens to be
obtained easily and noninvasively, as well as disease-related
biomarkers which may reveal the possibility of their use in
diagnosis and monitoring.
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